At a glance
ClinicalIndex Comparison RecordN/ACompleted· 19 enrolled
Drug / intervention
L-N^G monomethyl arginine (L-NMMA)drug
Likely dose
L-N^G monomethyl arginine (L-NMMA) 1 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Endothelial Function in Lower Extremity Bypass Grafts
In Brief
A clinical study evaluating L-N^G monomethyl arginine (L-NMMA) for Peripheral Arterial Disease. Completed, enrolled 19 participants across 1 site.
Detailed Summary
This study will determine whether or not saphenous vein \[arterial\] bypass grafts in the leg relax in response to increases in blood flow.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Arterial Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
First PostedSep 2008
Primary CompletionDec 2009
TodayJul 2026
First PostedSep 25, 2008
Enrollment StartApr 1, 2006
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 17.8 years ago
Interventions
L-N^G monomethyl arginine (L-NMMA)drug
L-NMMA was infused at a dose of 1 mg/kg over 10 minutes to competitively inhibit the production of nitric oxide. Ultrasound imaging of the saphenous vein \[arterial\] bypass at baseline, and following an ischemic stimulus, administration of sublingual nitroglycerin, and intravenous administration of L-NMMA.